|View printer-friendly version|
|CytomX Announces Upcoming Trials in Progress Poster Presentations at European Society for Medical Oncology Annual Meeting|
About the PROCLAIM-CX-072 Trial:
The PROCLAIM-CX-072 (PRObody CLinical Assessment In Man) study is designed to evaluate tolerability, and preliminary antitumor activity and translational biomarkers of multiple doses of CX-072 as monotherapy or as combination therapy with ipilimumab or vemurafenib in patients with advanced, unresectable solid tumors or lymphoma. This first-in-human, open-label, multicenter, dose-escalation, phase 1/2 study of CX-072 includes 4 dose-escalation groups (monotherapy, Part A; 2 ipilimumab combination schedules, Parts B1 and B2; vemurafenib combination, Part C), a stage testing biomarkers and efficacy in PD-L1+ tumors (Part A2), and a dose-expansion phase (Part D).
About the PROCLAIM-CX-2009 Trial:
The objectives of the ongoing PROCLAIM-CX-2009 (PRObody CLinical Assessment In Man) module are to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose-limiting toxicities, and preliminary antitumor activity of CX-2009 as monotherapy in the following 7 selected tumor types with high CD166 expression: breast carcinoma, castration-resistant prostate carcinoma (CRPC), cholangiocarcinoma, endometrial carcinoma, epithelial ovarian carcinoma, head and neck squamous cell carcinoma (HNSCC), and non–small cell lung carcinoma (NSCLC).